New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
Report details five instances of product hopping that collectively cost $4.7 billion annually.
- PBM Concerns Induce Surprising Bipartisanship
- MGA’s Latest Work Examining Digital Health Tools
- ‘The Price of Business’: Discussing the Debt Crisis
- A More Affordable Future Through Competition
- A Drug with Two Prices
- ‘The Price of Business’: Discussing the Future of Working at Home
- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
